IN8bio (NASDAQ:INAB) Stock Price Down 5.3% – Should You Sell?

Shares of IN8bio, Inc. (NASDAQ:INAB) fell 5.3% during mid-day trading on Monday . The stock traded as low as $1.23 and last traded at $1.26. 54,599 shares were traded during trading, an increase of 13% from the average session volume of 48,451 shares. The stock had previously closed at $1.33.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on INAB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating on shares of IN8bio in a research note on Thursday, June 4th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, IN8bio currently has a consensus rating of “Hold” and an average target price of $4.00.

IN8bio Price Performance

The stock has a market cap of $12.41 million, a price-to-earnings ratio of -0.48 and a beta of 0.22. The firm’s 50-day moving average is $1.49 and its 200 day moving average is $1.70.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.33. On average, sell-side analysts forecast that IN8bio, Inc. will post -1.53 EPS for the current year.

Institutional Investors Weigh In On IN8bio

A number of institutional investors have recently added to or reduced their stakes in the company. HRT Financial LP acquired a new stake in IN8bio during the fourth quarter worth about $34,000. Captrust Financial Advisors acquired a new position in shares of IN8bio in the 4th quarter valued at about $43,000. Citadel Advisors LLC purchased a new stake in shares of IN8bio during the 3rd quarter worth about $54,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in IN8bio during the 4th quarter worth approximately $56,000. Finally, Two Sigma Investments LP acquired a new stake in IN8bio during the 3rd quarter worth approximately $107,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.